Triple-negative breast cancer trials in Italy

In Italy 31 Also abroad 425

31 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Where
Candiolo, Milan, Naples, Rozzano
Age
18 years and over
People
15 worldwide
Run by
Valo Therapeutics Oy
See details and how to joinNCT05492682 · EU 2024-517580-23-00
Phase 3Taking people
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Where
Aviano, Bologna, Brescia, Florence, Meldola, Milan, Misterbianco, Monza, Naples, Novara, Rome
Age
18 years and over
People
1,530 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06393374 · EU 2023-504962-52-00
Phase 3Taking people
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Where
Bari, Bergamo, Bologna, Florence, Genoa, Meldola, Milan, Misterbianco, Modena, Naples, Rome, Trento, Turin
Age
18 years and over
People
1,514 worldwide
Run by
Gilead Sciences
See details and how to joinNCT05633654 · EU 2024-512279-10-00
Phase 1Taking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Milan
Age
18 years and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
Phase 3Taking people
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Where
Ancona, Aviano, Lucca, Milan, Monza, Pisa, Rome, Siena
Age
18 years and over
People
558 worldwide
Run by
BioNTech SE
See details and how to joinNCT07173751 · EU 2025-521884-12-00
Phase 1Not yet taking people in Italy
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
Where
Milan, Naples
Age
18 years and over
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-518348-19-00 · EU 2024-518348-19-00
Phase 3Taking people
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Where
Bologna, Genova, Milan, Misterbianco, Novara, Padova, Perugia, Roma, Rome
Age
18 years and over
People
1,000 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06841354 · EU 2024-516834-36-00
Phase 3Taking people
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Where
Ancona, Bergamo, Catanzaro, Genoa, Leghorn, Milan, Monza, Padova, Pisa, Reggio Emilia, Rome
Age
18 years and over
People
2,400 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06966700 · EU 2024-520190-12-00
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Candiolo, Milan, Naples, Rome, Rozzano
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 3Taking people
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Where
Bergamo, Empoli, Milan, Modena, Naples, Padova, Reggio Emilia, Roma, Rozzano
Age
18 years and over
People
625 worldwide
Run by
AstraZeneca
See details and how to joinNCT06103864
Phase 3Taking people
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Where
Bergamo, Empoli, Milan, Naples, Padova, Reggio Emilia, Rome, Rozzano
Age
18 years and over
People
58 worldwide
Run by
AstraZeneca AB
See details and how to join2023-503675-24-00 · EU 2023-503675-24-00
Phase 1/2Taking people
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Where
Aviano, Candiolo, Florence, Milan, Roma
Age
18 years and over
People
416 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06618287
No phaseTaking people
Role of Tumor Microbiota in the Response to Neoadjuvant Therapy in Patients Affected by Triple Negative Breast Cancer
Where
Pavia
Age
18 years and over
People
30
Run by
Istituti Clinici Scientifici Maugeri SpA
See details and how to joinNCT07808086
Phase 1Taking people
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Where
Candiolo, Rozzano
Age
18 years and over
People
540 worldwide
Run by
SystImmune Inc.
See details and how to joinNCT05983432
No phaseTaking people
Physical Activity and Healthy Aging: Promoting Cardio-metabolic Capacity to Fight Chronic Inflammation and Improve Outcomes in Breast Cancer Patients (PhActHealth Study)
Where
Milan, Urbino
Age
18 years and over
People
126
Run by
University of Milan
See details and how to joinNCT07776951
Phase 1/2Taking people
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Where
Candiolo, Milan, Naples, Roma, Rozzano, Siena
Age
18 years and over
People
1,109 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04895709
Phase 2/3Taking people
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Where
Aviano, Bologna, Genoa, Milan, Naples, Novara, Padova, Pontedera, Prato, Rome
Age
18 years and over
People
600 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06926868 · EU 2024-519871-24-00
Phase 1Taking people
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Where
Milan, Reggio Emilia
Age
18 years to 100 years
People
162 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06562192
Phase 1Taking people
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Where
Bologna, Milan, Verona
Age
18 years and over
People
714 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00
Phase 2Taking people
“A Phase II trial of atezolizumab plus CArboplatin plus nab-Paclitaxel as first-line Therapy in metastatic triple-negative PD-L1 positive breast cancer patients”
Where
Avellino, Aviano, Bologna, Cuneo, Faenza, Genoa, Meldola, Naples, Parma, Pozzuoli, Reggio Emilia, Rimini, Roma, Terni, Turin, Vicenza, Ospedale S. Timoteo di Termoli
Age
18 years and over
People
104
Run by
Consorzio Oncotech
See details and how to join2024-519514-31-00 · EU 2024-519514-31-00
Phase 1Taking people
THE-0504 in Patients With Solid Tumors
Where
Rome
Age
18 years and over
People
30
Run by
Thena Biotech S.r.l.
See details and how to joinNCT07646106 · EU 2023-503787-17-00
No phaseTaking people
Biomarkers of Efficacy and Tolerability of Sacituzumab-Govitecan in the Treatment of Patients With Triple-negative Breast Cancer in the Metastatic Phase: Prospective Multicenter Real-world Study
Where
Rome
Age
18 years and over
People
60
Run by
Regina Elena Cancer Institute
See details and how to joinNCT06240195
No phaseNot yet taking people in Italy
ON-treatment Single-cell Analysis for the Identification of Early Tumor Response Biomarkers on Prospective Collected Serial Tumor Biopsies in Triple Negative Breast Cancer Patient During Standard Neoadjuvant Chemo-immunotherapy
Where
Milan
Age
18 years and over
People
55
Run by
IRCCS San Raffaele
See details and how to joinNCT07597642
No phaseTaking people
fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases
Where
Milan
Age
18 years to 75 years
People
145
Run by
European Institute of Oncology
See details and how to joinNCT06328465
Phase 2Taking people
Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients
Where
Brindisi, Milan, Monza, Roma
Age
18 years and over
People
45
Run by
European Institute of Oncology
See details and how to joinNCT06690840